HK1204449A1 - Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor ad36e4orf1 akt1 - Google Patents

Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor ad36e4orf1 akt1

Info

Publication number
HK1204449A1
HK1204449A1 HK15105002.8A HK15105002A HK1204449A1 HK 1204449 A1 HK1204449 A1 HK 1204449A1 HK 15105002 A HK15105002 A HK 15105002A HK 1204449 A1 HK1204449 A1 HK 1204449A1
Authority
HK
Hong Kong
Prior art keywords
ad36e4orf1
akt1
glycemic control
inhibitor
enhanced glycemic
Prior art date
Application number
HK15105002.8A
Other languages
English (en)
Chinese (zh)
Inventor
Nikhil Dhurandhar
Rashmi Krishnapuram
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of HK1204449A1 publication Critical patent/HK1204449A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15105002.8A 2012-01-20 2015-05-26 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor ad36e4orf1 akt1 HK1204449A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588959P 2012-01-20 2012-01-20
PCT/US2013/022126 WO2013109876A1 (en) 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor

Publications (1)

Publication Number Publication Date
HK1204449A1 true HK1204449A1 (en) 2015-11-20

Family

ID=47664431

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105002.8A HK1204449A1 (en) 2012-01-20 2015-05-26 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor ad36e4orf1 akt1

Country Status (8)

Country Link
US (1) US9433659B2 (de)
EP (1) EP2804616B1 (de)
JP (1) JP6175076B2 (de)
AU (1) AU2013209580B2 (de)
BR (1) BR112014017683A2 (de)
CA (1) CA2865202A1 (de)
HK (1) HK1204449A1 (de)
WO (1) WO2013109876A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064836A1 (en) 2005-11-30 2007-06-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
US20150038412A1 (en) 2015-02-05
JP6175076B2 (ja) 2017-08-02
AU2013209580A1 (en) 2014-08-07
BR112014017683A2 (pt) 2017-06-27
EP2804616B1 (de) 2018-07-18
JP2015505535A (ja) 2015-02-23
EP2804616A1 (de) 2014-11-26
WO2013109876A1 (en) 2013-07-25
AU2013209580B2 (en) 2017-11-30
CA2865202A1 (en) 2013-07-25
US9433659B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
IL233051A0 (en) Anti-phf-tau antibodies and uses thereof
GB2500915B (en) Arrangement and method
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
GB2509400B (en) Rigid-stem lead-in-method and system
EP2709712A4 (de) Hüllendilatatorsystem sowie verwendungen davon
EP2884135A4 (de) Thermoregulator und thermoregulatorkomponente
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1210949A1 (en) Combinations and uses thereof
GB201110783D0 (en) Methods and uses
EP2726008A4 (de) Elektrochirurgische systeme und verfahren
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
EP2708532A4 (de) 4-aminochinazolin-derivate und verwendungen davon
EP2877214A4 (de) Prognose und behandlung von mit diabetes assoziierten komplikationen
EP2688588A4 (de) Schnell und lange wirkendes immunologisches therapeutikum
GB201116774D0 (en) Uses and methods
TWI562080B (en) Systes and methods for operation activation
EP2716359A4 (de) Komplex und verwendungen davon
EP2697386A4 (de) Pepducin-entwurf und -verwendung
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
SG11201500474PA (en) Nutriculture member and nutriculture method
GB201222836D0 (en) Polyester and film -iia
EP2693879A4 (de) Migrastatine und verwendungen davon
HK1204449A1 (en) Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor ad36e4orf1 akt1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230116